Pharmaceuticals

Daewoong Pharmaceutical and Hanall Biopharma Invest $1M USD in Alloplex Biotherapeutics

SEOUL, South Korea, Aug. 19, 2021 /PRNewswire/ -- Daewoong Pharmaceutical and Hanall Biopharma ofSouth Korea are expanding their global open collaboration initiative by investing in Alloplex Biotherapeutics, an emergingBoston-based biotechnology company.

2021-08-19 21:00 3095

PharmAbcine Announces Submission of PCT for an Anti-ANG2 Antibody for the Treatment of Ocular Diseases

DAEJEON, South Korea, Aug. 19, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, today announced it submitted a Patent Cooperation Treaty (PCT), an international patent application, for ...

2021-08-19 20:00 1846

I-Mab Announces Establishment of Environmental, Social and Governance Committee

* I-Mab received highest first-time ESG rating among China-based biotech companies from MSCI * New majority independent ESG committee to set overall ESG strategies for the Company * Women account for two-thirds of the total workforce and over 30% of I-Mab's Board of Directors * Committed ...

2021-08-19 19:00 4917

Zhaoke Ophthalmology's Phase III Clinical Trial of Cyclosporine A (CsA) Ophthalmic Gel for Dry Eye Disease Meets Primary Endpoint

Largest Ever Completed Dry Eye Disease (DED) clinical trial to date in China Zhaoke Ophthalmology's in-house developed innovative drug candidate Targeting NDA Filing by the End of 2021 Dry Eye Disease Affects Over 200 Million People in China Potential to become new standard of care for moderate-to-s...

2021-08-19 12:43 4641

Senhwa's Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma

TAIPEI and SAN DIEGO, Aug. 18, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced that the US Food and Drug Administration (FDA) has granted Fast Tr...

2021-08-19 10:57 2347

MicroConstants to Join BioAgilytix Family

Highly complementary transaction strengthens BioAgilytix's ability to support bioanalytical services across all major therapeutics in development; adds LC/MS/MS capabilities; and expands team of seasoned scientists DURHAM, N.C., Aug. 18, 2021 /PRNewswire/ -- BioAgilytix Labs, LLC (BioAgilytix),...

2021-08-19 02:30 2165

MicroConstants to Join BioAgilytix Family

Highly complementary transaction strengthens BioAgilytix's ability to support bioanalytical services across all major therapeutics in development; adds LC/MS/MS capabilities; and expands team of seasoned scientists DURHAM, N.C., Aug. 19, 2021 /PRNewswire/ -- BioAgilytix Labs, LLC (BioAgilytix), ...

2021-08-19 02:30 2318

Henlius reports half-year (H1) 2021 results, outlines remarkable growth in commercialization and needs-driven innovation

SHANGHAI, Aug. 18, 2021 /PRNewswire/ -- Henlius (2696.HK) announced Half-Year (H1) results endedJune 30th, 2021, sharing the company's recent noteworthy progress and achievements. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innov...

2021-08-18 21:35 4524

Seegene Q2 2021 Earnings Show 11 Percent Revenue Growth, YoY

-  Revenue of KRW 303.7 billion ($269.1 million) is record for second quarter, up 11 percent year-over-year -  1H'21 Revenue at KRW 655.5 billion ($580.8 million), 58 percent achievement based on total sales in FY2020 -  Favorable market conditions expected in second half amid an increasing dem...

2021-08-18 18:00 2287

Transcenta Held Investigator Meeting and Initiated Phase IIa Clinical Trial of Claudin18.2 Monoclonal Antibody TST001 with First Patient Dosed Successfully

SUZHOU, China, Aug. 18, 2021 /PRNewswire/ -- Transcenta announced that it held an investigator meeting successfully for TST001 Phase I clinical trial study on August 14. Professors Lin Shen and Jifang Gong from Beijing Cancer Hospital, ProfessorWeijian Guo from Fudan University Shanghai Cancer Cen...

2021-08-18 08:00 2991

Significant Weight Loss and Multiple Metabolic Benefits: Phase 1b Study Results of IBI362 in Chinese Participants with Overweight or Obesity Published in EClinicalMedicine by the Lancet

SAN FRANCISCO and SUZHOU, China, Aug. 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...

2021-08-18 08:00 5096

PT Anugerah Pharmindo Lestari (APL) Won 'Community Initiative' Award and 'Outstanding Leader in Asia' Title for Its President Director at the Asia Corporate Excellence & Sustainability Awards 2021

JAKARTA, Indonesia, Aug. 17, 2021 /PRNewswire/ -- PT Anugerah Pharmindo Lestari (APL), a member of Zuellig Pharma, a leading healthcare services company in Indonesia, has been awarded with the 'Community Initiative' and 'Outstanding Leader inAsia' for APL's President Director, Christophe Piganiol,...

2021-08-17 22:02 3791

Holmusk signs agreements with UTHealth and The Harris Center

NEW YORK, Aug. 17, 2021 /PRNewswire/ -- Holmusk, a leading global data science and health technology company building the world's largest Real-World Evidence (RWE) platform for behavioral health, has signed data license agreements with TheUniversity of Texas Health Science Center at Houston (UTHe...

2021-08-17 21:00 2182

I-Mab to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021

SHANGHAI and GAITHERSBURG, Md., Aug. 17, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced it will provide business and corporate updates and repo...

2021-08-17 20:00 3432

PharmAbcine to Participate in Biotechgate Digital Partnering

DAEJEON, South Korea, Aug. 17, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participate in Biotechgate Digital Partnering taking place virtuall...

2021-08-17 20:00 1852

Innoforce Pharmaceuticals Opens Analytical Development and Process Development Facility in Hangzhou, China

HANGZHOU, China and ROCKVILLE, Md., Aug. 17, 2021 /PRNewswire/ -- Innoforce Pharmaceuticals ("Innoforce"), a biopharmaceutical innovation and partnership company, today announces that it has opened a new Advanced Cell and Gene Therapy Development Facility inHangzhou, China. Analytical development...

2021-08-17 19:00 3010

SINOMED announces the first commercial implantation and European launch of the HT Supreme Drug Eluting Stent

TIANJIN, China, Aug. 17, 2021 /PRNewswire/ -- SINOMED, a leading international medical device company, announced the first commercial implantation of the HT Supreme® Drug-Eluting Stent (DES) at University Hospital Galway in partnership with theNational University of Ireland Galway (NUI Galway), m...

2021-08-17 18:00 3144

Angel Pharmaceuticals Announces IND Acceptance for Clinical Trial of ITK Inhibitor CPI-818 in China

JIAXING, China and BURLINGAME, Calif., Aug. 16, 2021 /PRNewswire/ -- Angel Pharmaceuticals Ltd. ("Angel Pharma") today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted its IND application for the initiation of a Phase 1/...

2021-08-17 05:00 2190

111, Inc. Deepens Partnership with Bayer Healthcare

SHANGHAI, Aug. 16, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced the expansion of its existing partnership with Baye...

2021-08-16 20:00 7453

Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors

SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Aug. 16, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...

2021-08-16 20:00 3288